Fractyl Health Strengthens Revita Patent Portfolio
Fractyl Health reported the strengthening of its patent portfolio for its Revita DMR system as it progresses toward FDA submission.
Stocks · News reference
Morgan Stanley Maintains Equal-Weight on Fractyl Health, Lowers Price Target to $4
Morgan Stanley analyst Michael Ulz maintains Fractyl Health (NASDAQ:GUTS) with a Equal-Weight and lowers the price target from $24 to $4.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Fractyl Health Announces Results of Market Research on GLP-1 Therapy Discontinuation
Fractyl Health released findings from a market survey indicating significant patient interest in a one-time procedural approach for weight maintenance following GLP-1 therapy.
Fractyl Health Announces Strategic Reprioritization and Workforce Reduction
Fractyl Health is sharpening its focus on its lead product candidate, Revita, while discontinuing its Rejuva gene therapy program and reducing its workforce by approximately 45%.
Fractyl Health Names Harith Rajagopalan President
Fractyl Health has appointed Harith Rajagopalan as president following the retirement of Jay Caplan.
Fractyl Health Announces Heightened Focus On Advancing Revita Toward Potential FDA Marketing Authorization And Commercialization In Post-GLP-1 Weight Maintenance
8-K filing — FRACTYL HEALTH, INC. (GUTS)
Filed: 2026-10-22 AccNo: 0001193125-26-428302 Size: 238 KB Item 2.05: Cost Associated with Exit or Disposal Activities Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits